Ikoma, Japan

Masatomo Kato

USPTO Granted Patents = 17 

 

 

Average Co-Inventor Count = 5.9

ph-index = 2

Forward Citations = 12(Granted Patents)


Location History:

  • Nara, JP (2022)
  • Ikoma, JP (2011 - 2023)

Company Filing History:


Years Active: 2011-2025

Loading Chart...
Loading Chart...
Loading Chart...
17 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Masatomo Kato

Introduction

Masatomo Kato is a prominent inventor based in Ikoma, Japan, known for his significant contributions to the field of ophthalmology. With a total of 17 patents to his name, Kato has made remarkable advancements in the treatment and prevention of eye diseases.

Latest Patents

Among his latest patents is an agent containing 4-phenylbutyrate, aimed at preventing or treating presbyopia. This innovative agent comprises 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof, providing a new approach to managing age-related vision issues. Another notable patent focuses on an agent for preventing myopia, treating myopia, and preventing myopia progression, which includes tiotropium as an active ingredient. This invention represents a significant step forward in addressing the growing concern of myopia in various populations.

Career Highlights

Throughout his career, Masatomo Kato has worked with esteemed organizations such as Santen Pharmaceutical Co., Ltd. and Singapore Health Services Pte Ltd. His work in these companies has allowed him to collaborate on groundbreaking research and development projects that have the potential to improve eye health globally.

Collaborations

Kato has collaborated with notable colleagues, including Miwa Takai and Mamoru Matsuda, contributing to a dynamic exchange of ideas and expertise in the field of ophthalmology.

Conclusion

Masatomo Kato's innovative work and dedication to advancing eye care through his patents and collaborations highlight his significant impact on the field. His contributions continue to pave the way for new treatments and improved patient outcomes in ophthalmology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…